Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (6717)	7/9/1998 5:29:00 PM
From: James Wright	Read Replies (1) \| Respond to of 29382

Max -- Like you, I rarely buy companies trading in the 30s or above, but KNDL's numbers and chart convinced me to make a rare exception. I work with a number of similar contract laboratories that evaluate health and safety issues associated with pesticides (my area of legal expertise). Thus, I know something about contract laboratories (although I have not worked with KNDL and I have no specific knowledge about KNDL other than what's publicly available). I believe that biotech is going to be the next big wave over the coming years (like Internet stocks are today). It's already revolutionizing the argi-chem area where I represent companies as an attorney. Primary pharmaceutical and agri-chem companies often find it is more cost effective to contract their work out to laboratories like KNDL. Thus, KNDL is a way to ride that growing wave without having to figure out which primary pharmaceutical or agri-chem companies are ultimately going to make it to market with blockbuster products. Bottomline: The work is going to be going to laboratories like KNDL regardless of the success or failure of individual pharmaceutical and agri-chem companies. Thus, KNDL is a low-risk way to buy into the emerging high growth biotech sector and ride that sector to increased profits. Anyway, that's my opinion. -- Jim